Literature DB >> 28260080

Dysregulation of TMPRSS3 and TNFRSF11B correlates with tumorigenesis and poor prognosis in patients with breast cancer.

Ping Luo1, Gaixia Lu2, Lin-Lin Fan3, Xiaoming Zhong4, Huiqiong Yang2, Ruting Xie2, Zhongwei Lv2, Qian-Zhou Lv3, Da Fu2, Li-Xin Yang5, Yushui Ma2.   

Abstract

The present study was carried out to investigate the clinical significance of TMPRSS3 and TNFRSF11B in breast cancer. Thus, the expression levels of TMPRSS3 and TNFRSF11B and the correlation with prognosis in patients with breast cancer were analyzed in silico using gene microarray and hierarchical clustering analysis. Then, the differential expression in breast cancer vs. normal breast tissue was explored in the Oncomine platform and verified in our independent samples using IHC technique. Our results indicated that TMPRSS3 was upregulated and TNFRSF11B was downregulated in breast cancer tissues compared with the levels in the human normal breast tissues. TMPRSS3 and TNFRSF11B were confirmed to be correlated with distant organ metastasis of breast cancer. Moreover, upregulation of TMPRSS3 accompanied by downregulation of TNFRSF11B was found to be associated with a shorter median overall survival and indicated a poor prognosis. In conclusion, TMPRSS3 and TNFRSF11B may have potential prognostic value to be used as tumor biomarkers in breast cancer patients.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28260080     DOI: 10.3892/or.2017.5449

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  8 in total

Review 1.  Cell surface-anchored serine proteases in cancer progression and metastasis.

Authors:  Carly E Martin; Karin List
Journal:  Cancer Metastasis Rev       Date:  2019-09       Impact factor: 9.264

2.  Identification of endothelial selectin as a potential prognostic marker in breast cancer.

Authors:  Wei Zhang; Zhichao Zuo; Xiangyang Huang; Junjie Liu; Guanqiao Jin; Danke Su
Journal:  Oncol Lett       Date:  2018-04-25       Impact factor: 2.967

Review 3.  Osteoprotegerin: Relationship to Breast Cancer Risk and Prognosis.

Authors:  Dirk Geerts; Christina Chopra; Linda Connelly
Journal:  Front Oncol       Date:  2020-04-07       Impact factor: 6.244

4.  Potential Molecular Mechanism of TNF Superfamily-Related Genes in Glioblastoma Multiforme Based on Transcriptome and Epigenome.

Authors:  Hui Xie; Ce Yuan; Jin-Jiang Li; Zhao-Yang Li; Wei-Cheng Lu
Journal:  Front Neurol       Date:  2021-02-11       Impact factor: 4.003

5.  Novel estrogen-responsive genes (ERGs) for the evaluation of estrogenic activity.

Authors:  Kentaro Nishi; Wenqiang Fu; Ryoiti Kiyama
Journal:  PLoS One       Date:  2022-08-17       Impact factor: 3.752

6.  Identification of Potential Bisphenol A (BPA) Exposure Biomarkers in Ovarian Cancer.

Authors:  Aeman Zahra; Qiduo Dong; Marcia Hall; Jeyarooban Jeyaneethi; Elisabete Silva; Emmanouil Karteris; Cristina Sisu
Journal:  J Clin Med       Date:  2021-05-05       Impact factor: 4.241

7.  Comprehensive germline genomic profiles of children, adolescents and young adults with solid tumors.

Authors:  Sara Akhavanfard; Roshan Padmanabhan; Lamis Yehia; Feixiong Cheng; Charis Eng
Journal:  Nat Commun       Date:  2020-05-05       Impact factor: 14.919

8.  Receptor activator of nuclear factor kB ligand, osteoprotegerin, and risk of death following a breast cancer diagnosis: results from the EPIC cohort.

Authors:  Danja Sarink; Helena Schock; Theron Johnson; Jenny Chang-Claude; Kim Overvad; Anja Olsen; Anne Tjønneland; Patrick Arveux; Agnès Fournier; Marina Kvaskoff; Heiner Boeing; Anna Karakatsani; Antonia Trichopoulou; Carlo La Vecchia; Giovanna Masala; Claudia Agnoli; Salvatore Panico; Rosario Tumino; Carlotta Sacerdote; Carla H van Gils; Petra H M Peeters; Elisabete Weiderpass; Antonio Agudo; Miguel Rodríguez-Barranco; José María Huerta; Eva Ardanaz; Leire Gil; Kay Tee Kaw; Julie A Schmidt; Laure Dossus; Mathilde His; Dagfinn Aune; Elio Riboli; Rudolf Kaaks; Renée T Fortner
Journal:  BMC Cancer       Date:  2018-10-22       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.